Nearly a year ago, the Centers for Medicare & Medicaid Services denied coverage for an Eli Lilly LLY +0.10%imaging agent to be used in diagnosing Alzheimer’s. In reaching its decision, CMS cited a lack of evidence that the agent, called Amyvid, could improve health outcomes. As a result, CMS greatly narrowed the potential use of the agent, dealing Lilly a significant setback. {read more here}